KN046
Various cancers (PD-L1/CTLA-4 bispecific)
Phase 2Active
Key Facts
About AlphaMab Oncology
AlphaMab Oncology develops innovative bispecific antibodies and ADCs for cancer treatment using proprietary glycan-specific conjugation and CRIB platforms.
View full company profile